RGNX - Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity Retinal Thickness | Benzinga
Regenxbio Inc (NASDAQ:RGNX) released Tuesday, Jan. 16, interim data from the Phase 2 AAVIATE trial of ABBV-RGX-314 for wet age-related macular degeneration (wet AMD) using suprachoroidal delivery.
Investigational ABBV-RGX-314 using suprachoroidal delivery is designed as a one-time, in-office treatment.
The new data presented includes six-month results from two additional dose level 3 cohorts (Cohorts 5 and 6).
ABBV-RGX-314, being developed in collaboration with AbbVie Inc (NYSE:ABBV), is also being investigated as a potential one-time gene therapy for diabetic retinopathy and other chronic retinal conditions.
ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events
ABBV-RGX-314 in over 50 patients at the third dose level demonstrated the highest reduction in ...